NCT00659321

Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome

Placebokontrollierte Untersuchung Zur Wirkung Von Nikotinsäure Auf Die Dyslipidämie Bei Metabolischem Syndrom Und Das Arterioskleroserisiko (Placebo Controlled Investigation of Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome and the Risk of Atherosclerosis)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: GWT-TUD GmbH · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Placebo controlled evaluation of effectiveness of nicotine acid in treatment of postprandial dyslipidemia in patients with metabolic syndrome. Nicotine acid decreases postprandial hyperlipidaemia in patients with metabolic syndrome which reduces the low-grade inflammation and the risk of atherosclerosis.

Conditions

• Metabolic Syndrome
• Dyslipidaemia

Interventions

Type	Name	Description
DRUG	nicotine acid	16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
DRUG	placebo	16 weeks treatment with placebo

Timeline

• Start date: 2007-01-01
• Primary completion: 2008-09-01
• Completion: 2008-12-01
• First posted: 2008-04-16
• Last updated: 2012-01-11

Locations

1 site across 1 country: Germany